NEW YORK, May 19, 2014 (GLOBE NEWSWIRE) -- Legacy Platinum Group Inc. (OTCPINK:LWSP) reports that the Company has changed its name to Wee-Cig International Corporation (Wee-Cig) and its symbol to WCIG to reflect its new business direction.
A Certificate of Amendment to its Articles of Incorporation was filed with the State of Nevada changing the name to Wee-Cig International Corporation effective May 16, 2014 and the CUSIP Number has changed from 524704 20 2 to 94846 10 9.
This name change will not involve a change in the issued or authorized capital of the Company. The Company's new trading symbol will be "WCIG", effective May 20, 2014.
Furthermore, to clarify, the previous announcements on pending acquisitions of a platinum property and social media deal are now null and void.
Update: Wee-Cig Business
Wee-Cig took part in the Vapor World Expo in Chicago, a key annual industry event, that had over 200 suppliers of vaporization products and accessories, bringing together a mix of Manufacturers, Distributors, Wholesalers and Retailers and will likely be an industry-focused event, designed to further strong business ties and industry groups within the e-cigarette and vapor product marketplace.
"Through events like these, among other marketing methods, Wee-Cig seeks to explore further advances in vaping technology and continue to build its distribution network. Wee-Cig will continue to seek opportunities and joint ventures with other companies that will further increase revenue, product line, and brand recognition," states Matt Kelly. "Since the Company's main focus is now vaporizers and e-cigs, the new name change will better reflect this exciting business."
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained herein which are not historical fact are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays in testing and evaluation of products and other risks detailed from time to time in Legacy's filings with the OTC Markets.